- Home
- DKL vs IBRX Comparison
DKL vs IBRX Comparison
Compare DKL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DKL
- IBRX
- Stock Information
- Founded
- DKL 2012
- IBRX 2014
- Country
- DKL United States
- IBRX United States
- Employees
- DKL N/A
- IBRX N/A
- Industry
- DKL Natural Gas Distribution
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DKL Energy
- IBRX Health Care
- Exchange
- DKL Nasdaq
- IBRX Nasdaq
- Market Cap
- DKL 2.2B
- IBRX 1.9B
- IPO Year
- DKL N/A
- IBRX N/A
- Fundamental
- Price
- DKL $45.37
- IBRX $2.94
- Analyst Decision
- DKL Buy
- IBRX Strong Buy
- Analyst Count
- DKL 4
- IBRX 3
- Target Price
- DKL $44.00
- IBRX $13.58
- AVG Volume (30 Days)
- DKL 178.4K
- IBRX 6.3M
- Earning Date
- DKL 02-25-2025
- IBRX 11-12-2024
- Dividend Yield
- DKL 9.71%
- IBRX N/A
- EPS Growth
- DKL N/A
- IBRX N/A
- EPS
- DKL 2.83
- IBRX N/A
- Revenue
- DKL $984,922,000.00
- IBRX $7,332,000.00
- Revenue This Year
- DKL N/A
- IBRX $2,515.60
- Revenue Next Year
- DKL $2.39
- IBRX $766.19
- P/E Ratio
- DKL $16.00
- IBRX N/A
- Revenue Growth
- DKL N/A
- IBRX 1218.71
- 52 Week Low
- DKL $37.02
- IBRX $2.28
- 52 Week High
- DKL $47.67
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- DKL 83.90
- IBRX 48.30
- Support Level
- DKL $41.66
- IBRX $2.28
- Resistance Level
- DKL $42.75
- IBRX $2.54
- Average True Range (ATR)
- DKL 0.98
- IBRX 0.25
- MACD
- DKL 0.33
- IBRX 0.10
- Stochastic Oscillator
- DKL 98.61
- IBRX 64.71
About DKL Delek Logistics Partners L.P. Common Units representing Limited Partner Interests
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes Pipelines and Transportation; Pipelines and Transportation and Investments in Pipeline Joint Ventures. It generates maximum revenue from the Pipelines and Transportation segment. The pipelines and Transportation segment consist of pipelines, tanks, offloading facilities, trucks, and ancillary assets, which provide crude oil gathering and crude oil, intermediate and refined products transportation and storage services in support of Delek Holdings' refining operations in Tyler, Texas, El Dorado, Arkansas and Spring, Texas.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.